Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CAR-T Meeting 2024 | Manufacturing autologous CAR-T cells: challenges and novel platforms being explored

Pere Barba • 15 Feb 2024
CAR-T Meeting 2024
General CAR-T

Pere Barba, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain, highlights challenges associated with the manufacturing of autologous CAR-T cells, and further discusses novel platforms and approaches being explored, including allogeneic products. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Allogene, Amgen, BMS/Celgene, Kite/Gilead, Incyte, Novartis, Pierre Fabre

More from Pere Barba

1:18
Is estimated exposure an accurate surrogate for measured fludarabine levels in CAR-T patients?
Pere Barba • 15 Feb 2024
1:09
How frontline therapy impacts the management of patients with ALL prior to CAR-T
Pere Barba • 15 Feb 2024
0:37
Factors to consider when managing patients with ALL prior to CAR T-cell therapy
Pere Barba • 15 Feb 2024
0:43
Phase I study of rapcabtagene autoleucel in patients with R/R DLBCL
Pere Barba • 12 Dec 2022

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals